Dowling & Yahnke’s Cardiff Oncology CRDF Stock Holding History

Dowling & Yahnke’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,378	Closed	-$43K	–	257
2018 Q4	$43K	Hold	10,378	–	–	﹤0.01%	247
2018 Q3	$51K	Buy	+10,378	New	+$49.2K	﹤0.01%	279

Other funds holding CRDF

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dowling & Yahnke's CRDF Position: Q1 2019 in Review

Dowling & Yahnke sold out of Cardiff Oncology (CRDF) in Q1 2019, closing a stake of 10,378 shares — an estimated $43K sold.

Dowling & Yahnke first reported a position in CRDF in Q3 2018 and held it in 2 quarters. The position peaked at $51K in Q3 2018. 21 funds tracked by Wall St. Rank hold CRDF as of Q1 2019.

Dowling & Yahnke reported no remaining Cardiff Oncology position as of Q1 2019 after selling out during the quarter.
Dowling & Yahnke sold 10,378 Cardiff Oncology shares in Q1 2019, an estimated $43K.
Dowling & Yahnke first reported a position in Cardiff Oncology in Q3 2018 and held it in 2 quarters.
Dowling & Yahnke's Cardiff Oncology position peaked at $51K in Q3 2018.
21 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2019.

Based on Dowling & Yahnke's 13F filing for Q1 2019, filed 30 Apr 2019.